GLS

By Targets:	Apoptosis (3) Autophagy (2) Bacterial (1) DNA/RNA Synthesis (1) Glutaminase (13) HBV (1) PD-1/PD-L1 (1) Small Interfering RNA (siRNA) (4)
By Research Areas:	Cancer (14) Infection (2) Inflammation/Immunology (2) Metabolic Disease (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P2760

Glutaminase

GLS
Others Others

Glutaminase (GLS) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
HY-144666

GLS-1-IN-1

Glutaminase Cancer

GLS-1-IN-1 (compound 1d) is a GLS-1 inhibitor. GLS-1-IN-1 shows inhibitory effect against Hep G2, MCF 7, and MCF 10A cells .

Glutaminase GLS	Others	Others
Glutaminase (GLS) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

GLS-1-IN-1	Glutaminase	Cancer
GLS-1-IN-1 (compound 1d) is a *GLS-1* inhibitor. GLS-1-IN-1 shows inhibitory effect against Hep G2, MCF 7, and MCF 10A cells .

HY-146617

GLS1 Inhibitor-4	Glutaminase Apoptosis	Cancer
GLS1 Inhibitor-4 (compound 41e) is a potent *GLS1* inhibitor with an IC₅₀ of 11.86 nM. GLS1 Inhibitor-4 shows antiproliferative activity, good metabolic stability, robust GLS1 binding affinity. GLS1 Inhibitor-4 blocks the glutamine metabolism and induce the production of ROS. GLS1 Inhibitor-4 induces apoptosis and shows antitumor activity .

HY-146616

GLS1 Inhibitor-3

Glutaminase Cancer

GLS1 Inhibitor-3 (compound C147) is a potent GLS1 inhibitor with an IC₅₀ of 27.98 nM. GLS1 Inhibitor-3 shows antiproliferative activity .

GLS1 Inhibitor-3	Glutaminase	Cancer
GLS1 Inhibitor-3 (compound C147) is a potent *GLS1* inhibitor with an IC₅₀ of 27.98 nM. GLS1 Inhibitor-3 shows antiproliferative activity .

HY-151434

GLS1 Inhibitor-6	Glutaminase Apoptosis	Cancer
GLS1 Inhibitor-6 (Compound 24y) is an orally active, potent and selective glutaminase 1 (GLS1) inhibitor (IC₅₀=68 nM), shows 220-fold selectivity for GLS2. GLS1 Inhibitor-6 shows good anti-tumor activity, antitumor cell proliferation activity and induces apoptosis .

HY-155138

GLS1 Inhibitor-7	Glutaminase	Metabolic Disease Cancer
GLS1 Inhibitor-7 (compound 4d) is a GLS1 inhibitor (IC₅₀=46.7 μM), with potential anti-cancer, anti-aging and anti-obesity properties .

HY-RS05500

GLS Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
GLS Human Pre-designed siRNA Set A contains three designed siRNAs for GLS gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

GLS Human Pre-designed siRNA Set A GLS Human Pre-designed siRNA Set A

HY-RS05501

Gls Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Gls Mouse Pre-designed siRNA Set A contains three designed siRNAs for Gls gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Gls Mouse Pre-designed siRNA Set A Gls Mouse Pre-designed siRNA Set A

HY-RS05502

Gls Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Gls Rat Pre-designed siRNA Set A contains three designed siRNAs for Gls gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Gls Rat Pre-designed siRNA Set A Gls Rat Pre-designed siRNA Set A

HY-RS05503

GLS2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
GLS2 Human Pre-designed siRNA Set A contains three designed siRNAs for GLS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

GLS2 Human Pre-designed siRNA Set A GLS2 Human Pre-designed siRNA Set A

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .

HY-108917

Morphothiadin 5 Publications Verification GLS4	HBV	Infection
Morphothiadin is a potent inhibitor on the replication of both wild-type and adefovir-resistant HBV with an IC₅₀ of 12 nM.

HY-128357

Ibezapolstat ACX-362E; GLS-362E	Bacterial DNA/RNA Synthesis	Infection
Ibezapolstat (ACX-362E) is a first-in-class, orally active DNA polymerase IIIC (pol IIIC) inhibitor, with a K_i of 0.325 μM for the DNA pol IIIC from C. difficile. Ibezapolstat is developed for the research of C. difficile infection(CDI) .

HY-103671A

IPN60090 dihydrochloride	Glutaminase	Inflammation/Immunology Cancer
IPN-60090 dihydrochloride is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC₅₀=31 nM), with no activity observed against GLS-2. IPN-60090 dihydrochloride exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 dihydrochloride can be used for solid tumors research, such as lung and ovarian cancers .

HY-103671

IPN60090	Glutaminase	Inflammation/Immunology Cancer
IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1 (GLS1; IC₅₀=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers .

HY-12248

Telaglenastat Maximum Cited Publications 58 Publications Verification CB-839	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits *GLS1* splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy and has antitumor activity .

HY-12248A

Telaglenastat hydrochloride CB-839 hydrochloride	Glutaminase Autophagy	Cancer
Telaglenastat (CB-839) hydrochloride is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat hydrochloride selectively inhibits *GLS1* splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC₅₀s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat hydrochloride inudces autophagy and has antitumor activity .

HY-148241

A-446

Glutaminase Cancer

A-446 is a potent glutaminase (GLS) inhibitor with an IC₅₀ value of 31 nM .
HY-146658

Glutaminase-IN-4

Glutaminase Cancer

Glutaminase-IN-4 (compound 2a) is a glutaminase (GLS) inhibitor with an IC₅₀ of 2.3 μM .

A-446	Glutaminase	Cancer
A-446 is a potent glutaminase (GLS) inhibitor with an IC₅₀ value of 31 nM .

Glutaminase-IN-4	Glutaminase	Cancer
Glutaminase-IN-4 (compound 2a) is a glutaminase (GLS) inhibitor with an IC₅₀ of 2.3 μM .

HY-79583

Glutaminase-IN-3 1 Publications Verification	Glutaminase	Cancer
Glutaminase-IN-3 (compound 657) is a potent glutaminase inhibitor with an IC₅₀ of 0.24 μM for Glutaminase 1 (GLS1). Glutaminase-IN-3 is extracted from patent WO2014089048A1, compound 657 .

HY-152207

LWG-301	Glutaminase Apoptosis	Cancer
LWG-301 is an allosteric inhibitor of Glutaminase 1 (GLS1) with an IC₅₀ value of 7 nM. LWG-301 significantly block glutamine metabolism, increases intracellular ROS, thus induces apoptosis. LWG-301 exhibits moderate antitumor effects in HCT116 xenograft model .

Cat. No.	Product Name

HY-L064

Glutamine Metabolism Compound Library	917 compounds
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH. Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment. MCE owns a unique collection of 917 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Glutamine Metabolism Compound Library

917 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 917 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Cat. No.	Product Name	Target	Research Area

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80690

	Glutaminase Antibody Glutaminase kidney isoform; GLS; GLS1; KGA; K-glutaminase; GAM; GAC; Glutaminase C; L-glutamine amidohydrolase	WB, ICC/IF, IP	Human, Mouse, Rat
	Glutaminase Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 73 kDa, targeting to Glutaminase. It can be used for WB,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat.


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.